Jagsonpal Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1nobfaj6ayfdkho9jbkl1cek.pdf

Key Takeaways


Growth Recovery & Drivers

Medhekar: "All the growth is completely strategic and structurally made in favor of yields. And I don't see any of the seasonal impact there."

Capital Allocation & Shareholder Returns

Gupta: "Keeping too much cash is also not productive, especially in the scenario of falling yields and also in a scenario wherein now we have access to bank finance to fund acquisitions."

Portfolio & Therapy Mix


New Product Pipeline & Field Force

Medhekar: "New product establishment is a very, very hard work for prescriptions to start flowing in from each and every pin code of the country, which will take possibly a year plus for us to do that."

Cost Structure & Margin Levers

Gupta: "Pharmaceutical industry for growth is not capital intensive. It is brand intensive. And brand requires execution excellence at a field force level... By pumping in more working capital, I cannot grow the business."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth1.5x IPM growth, translating to 12%-15% given IPM trending 6%-9%FY27
New product launchesApproximately 9-10 launches; half brand extensions, 5-6 new products in Gynaec/Ortho/DermaFY27
First-in-India product second waveAnnouncement of molecules in Gynaecology, Ortho, DermaBy May end or June first week
Cash recoupmentFull recoupment of cash paid out via buyback and enhanced dividendWithin 12 months
MR headcountNo increase in MR or manager numbers; all growth from productivity improvementOngoing
Ortho franchise build-outBuilt over next couple of quarters; all three franchises to "fire equally well"Next few quarters

Key Metrics

MetricQ4 FY26
Revenue₹64 cr, +10% YoY
EBITDAclose to ₹11 cr, +9% YoY, margin close to 16%
PATclose to ₹9 cr, +31% YoY, PAT margin approx. 14%
Revenue (full year FY26)approx. ₹287 cr, approx. +7% YoY
EBITDA (full year FY26)close to ₹61 cr, margin approx. 21%
Profit from operations (full year FY26)close to ₹45 cr, +19% YoY, margin approx. 16%
Gross margin (full year FY26)64.2%, 20-30 bps change due to product mix
Cash positionupwards of ₹190 cr as on March 31
Net working capital cycleclose to 11 days
MAT growth (Pharmarack)12.2%, outperforming market by 3.6%
Q4 growth (Pharmarack)14.2% against industry growth of 10.5%
Volume growth (Pharmarack, full year FY26)2%
Price growth (Pharmarack, full year FY26)6% to 7%
New product contribution to growth (Pharmarack, full year FY26)3.2%
Top 10 brands share of total salesapprox. 58% to 60%
Portfolio outside NLEM (price control)92%
Buyback₹40 cr at ₹250 per share, up to 16 lakh equity shares, no promoter participation
Dividend200% including one-time special dividend of 75%, total payout ₹4 per share, overall cash distribution approx. ₹26 cr
Total cash returned to shareholders (buyback + dividend)over ₹66 cr
ROE post buybackapprox. 18%, up from approx. 16%
ROCE post buybackclose to 26%, up from approx. 22%
New product launches in FY266 new products and 3 SKUs (brand extensions)
Planned launches for FY27approx. 9 to 10, half brand extensions in legacy brands, 5-6 new products within same therapies